Home · Health · Oct 8 archive
FDA Approves New Treatment for HER2-Positive Breast Cancer
Confirmed
In Short: The FDA has approved tucatinib (Tukysa, Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
The FDA has approved tucatinib (Tukysa, Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
Patients were randomly assigned evenly to receive tucatinib 300 mg or placebo orally twice daily on a background of trastuzumab and pertuzumab.
Overall, 42% of tucatinib patients experienced grade ≥ 3 adverse events compared to 24% in the placebo group; 13% of tucatinib subjects discontinued treatment due to adverse events, primarily hepatic side effects.
Tucatinib is already approved in combination with trastuzumab and capecitabine for HER2-positive advanced unresectable or metastatic breast cancer, including patients with brain metastases, after one or more prior anti-HER2 breast cancer treatments in the metastatic setting.
Hormone receptor-positive patients were allowed to continue endocrine therapy.
The trial 'puts exercise in a whole new evidentiary category,' according to Kathryn H., highlighting the importance of structured support in cancer treatment.
In the U.S. PATHFINDER 2 study, Galleri detected 35% of cancers diagnosed in participants during the following 12 months.
Researchers studying a widely used form of cancer immunotherapy found that certain diets normally associated with weight gain actually helped the treatment work better in mice.
'There is a synergistic relationship between the bacteria that reside in our GI tract, and the food we eat,' said Quail, Associate Professor in the Department of Physiology and Principal Investigator at the Rosalind & Morris Goodman Cancer Institute.
Alzheimer's patients on glucosamine also had a 25 percent higher risk of death, according to a study using AI to analyze more than a decade of patient health records from the UF Health system.
What this adds
The study involving tucatinib and its combination therapies adds to the growing body of research on targeted cancer treatments.
The PATHFINDER 2 study's results provide a benchmark for evaluating the effectiveness of new cancer detection technologies.
The dietary findings suggest potential new avenues for enhancing the efficacy of cancer treatments through diet modification.
Background
According to Oren Milstein, CEO of StemRad, a single major solar particle event can deliver more than one-third of NASA’s 600 millisievert career effective-dose limit, which corresponds to a 3% mortality risk from radiation-induced cancer.
What's confirmed
- The FDA has approved tucatinib (Tukysa, Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
- Patients were randomly assigned evenly to receive tucatinib 300 mg or placebo orally twice daily on a background of trastuzumab and pertuzumab.
- Overall, 42% of tucatinib patients experienced grade ≥ 3 adverse events compared to 24% in the placebo group; 13% of tucatinib subjects discontinued treatment due to adverse events, primarily hepatic side effects.
- Tucatinib is already approved in combination with trastuzumab and capecitabine for HER2-positive advanced unresectable or metastatic breast cancer, including patients with brain metastases, after one or more prior anti-HER2 breast cancer treatments in the metastatic setting.
- Hormone receptor-positive patients were allowed to continue endocrine therapy.
- The trial 'puts exercise in a whole new evidentiary category,' according to Kathryn H., highlighting the importance of structured support in cancer treatment.
- In the U.S. PATHFINDER 2 study, Galleri detected 35% of cancers diagnosed in participants during the following 12 months.
- Researchers studying a widely used form of cancer immunotherapy found that certain diets normally associated with weight gain actually helped the treatment work better in mice.
- 'There is a synergistic relationship between the bacteria that reside in our GI tract, and the food we eat,' said Quail, Associate Professor in the Department of Physiology and Principal Investigator at the Rosalind & Morris Goodman Cancer Institute.
- Alzheimer's patients on glucosamine also had a 25 percent higher risk of death, according to a study using AI to analyze more than a decade of patient health records from the UF Health system.
What's still developing
- But last week, it wasn’t marketing a prick to measure blood glucose or screen for celiac disease: It was launching one of a new generation of AI-based risk prediction algorithms for medical images.
- Tech is transforming health care and life sciences.
- Those taking it were 25 percent more likely to progress from mild cognitive impairment to full dementia.
- The CHALLENGE trial randomly assigned patients with colon cancer to either a 3-year exercise program that included 50-70 hours of structured support or a control group that received educational materials encouraging exercise.
- Test your knowledge with our new weekday mini crossword Utah regulators on Monday announced a plan to allow an artificial intelligence product to evaluate patients for acne treatment and write new drug prescriptions without prior human review.
- So far at least 22 people in four states have been sickened, and two patients have been hospitalized.
- Researchers are taking clues from the tumor itself, selecting unusual protein fragments and putting them into a vaccine.
- "With the limited number of patients, we must be cautious with further interpretation," David Braun of Yale University and Toni Choueiri of Dana-Farber Cancer Institute and Harvard Medical School, both in the US, told ScienceAlert in a joint response.
- These data will be highlighted in a late-breaking oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida and simultaneously published in the Journal of Clinical Oncology.
- Have you ever heard the expression: “ The operation was successful, but the patient died. ” It’s not a perfect analogy to the Lp(a) drug story…but it does convey the disappointment drug companies, doctors and patients are experiencing after this week’s Novartis announcement about the pelacarsen failure.
- Together, this hot mess leads to something cardiologists call “ high-risk plaque ” in coronary arteries ( European Journal of Preventive Cardiology, April 23, 2026 ).
- Fort Wayne, IN Legal News, Information & Blogs A blood test that can look for signs of dozens of cancers at once has moved an important step closer to formal FDA approval, but the closely divided vote over whether the test is effective shows why patients should view the technology with both optimism and care.